已收盘 05-08 16:00:00 美东时间
-0.152
-0.41%
Eyepoint Pharma (($EYPT)) has held its Q1 earnings call. Read on for the main h...
05-08 10:20
NPK International (NYSE:NPKI) released first-quarter financial results and host...
05-01 21:58
Medtronic enrolls first patient in ENDURANCE study of Altaviva tibial neuromodulation device Medtronic enrolled first patient in ENDURANCE post-approval study of Altaviva implantable tibial neuromodulation device for urge urinary incontinence. Clinical results have not been presented; study will tra
04-29 22:47
BRIEF-AOTI Reports Study In 3,126 Patients Shows Superior Durable Healing With TWO2 Therapy April 27 (Reuters) - Aoti Inc AOTI.L : AOTI INC - STUDY IN 3,126 PATIENTS SHOWS SUPERIOR DURABLE HEALING WITH TWO2 THERAPY AOTI INC - STUDY SHOWS 64.8% COMPLETE HEALING RATE, 2.7% RECURRENCE IN CHRONIC LOWER
04-27 14:22
BRIEF-ISS Extends, Expands Contract With Fulham Road Collaborative April 27 (Reuters) - Iss A/S ISS.CO : EXTENDS AND EXPANDS CONTRACT WITH THE FULHAM ROAD COLLABORATIVE IN THE UK CONTRACT HAS DURATION OF FIVE YEARS, WITH OPTION TO EXTEND FOR FURTHER FIVE YEARS Source text: ID:nGNX8l997v Further comp
04-27 13:02
Endurance Technologies Ltd. ( ($IN:ENDURANCE) ) has issued an update. Endurance...
04-16 22:31
LIVE MARKETS-New orders for durable goods dragged down by descending aircraft Major US stock indexes down; Nasdaq off >1% Cons Disc weakest S&P 500 sector; Energy leads gainers Euro STOXX 600 index down ~0.5% Dollar dips; bitcoin down ~2.5%; gold ~flat; US crude rallies ~3% US 10-Year Treasury yiel
04-07 22:54
BRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis Study March 30 (Reuters) - Connect Biopharma Holdings Ltd CNTB.O : RADEMIKIBART DEMONSTRATES BEST-IN-CLASS POTENTIAL IN PHASE 3 ATOPIC DERMATITIS STUDY CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART ACHIEVES RAPID, D
03-30 21:20
BRIEF-Barclays says Risks to Their $85/bbl Brent 2026 Forecast Skewed Higher March 26 (Reuters) - BARCLAYS: NOTWITHSTANDING UNCERTAINTIES ABOUT THE DURATION OF THE MIDDLE EAST CONFLICT, RISKS TO THEIR $85/B BRENT 2026 FORECAST SKEWED HIGHER SAYS EVEN WITH MAX DIVERSION VIA YANBU AND FUJAIRAH, PROLON
03-26 13:54
BRIEF-Barclays says Risks to Their $85/bbl Brent 2026 Forecast Skewed Higher March 26 (Reuters) - BARCLAYS: NOTWITHSTANDING UNCERTAINTIES ABOUT THE DURATION OF THE MIDDLE EAST CONFLICT, RISKS TO THEIR $85/B BRENT 2026 FORECAST SKEWED HIGHER SAYS EVEN WITH MAX DIVERSION VIA YANBU AND FUJAIRAH, PROLON
03-26 13:37